MADCAM1 and inflammatory bowel disease: Despite theoretically promising, the use of Vedolizumab, which antagonize MAdCAM-1 and its receptor α4β7 and it is approved for IBD treatment, did not show efficacy in patients with PSC and IBD (a phase 3 trial was retired in 2018).